George W. Bickerstaff


Mr. Bickerstaff has been instrumental in establishing the strategic, operating and financial direction of numerous private and public companies. During his career he has provided financial leadership for mergers and acquisitions valued at more than $50 billion and has funded and operated various venture capital businesses. Mr. Bickerstaff has served as a director of Cardax, Inc. since June 2014.

Mr. Bickerstaff is currently a Managing Director of M.M. Dillon & Co., LLC, which he joined in 2005. Prior to joining M.M. Dillon & Co., LLC, Mr. Bickerstaff held various positions with Novartis International AG, a global pharmaceuticals and consumer health company, including Chief Financial Officer of Novartis Pharma AG from October 2000 to May 2005. From December 1999 to September 2000, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Workscape, Inc. a provider of employee-related information services. From July 1998 to December 1999, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Uniscribe Professional Services, Inc., a nationwide provider of paper and technology-based document management solutions. From January 1998 to June 1998, Mr. Bickerstaff served as Executive Vice President and Chief Financial Officer of Intellisource Group, Inc., a provider of information technology solutions to the federal, state and local government and utility markets. From July 1997 to December 1997, Mr. Bickerstaff served as Vice President of Finance of Cognizant Corporation, a global business information services company. From January 1990 to June 1997, Mr. Bickerstaff served in various senior finance roles, including Chief Financial Officer of IMS Healthcare, a global business information services company in the healthcare and pharmaceutical industries. Prior to that, Mr. Bickerstaff held various finance, audit and engineering positions with the Dun & Bradstreet Corporation and General Electric Company.

Mr. Bickerstaff has been a member of the board of directors of CareDx, Inc., a company that develops, markets, and delivers diagnostic surveillance solutions for organ transplant recipients, since April 2014. Mr. Bickerstaff was a member of the board of directors of Vion Pharmaceuticals, Inc., from June 2005 to March 2010. Mr. Bickerstaff’s nonprofit activities include serving on the board of directors of the International Vaccine Institute, the International Centre for Missing and Exploited Children, The Center for Disease Dynamics, Economics & Policy and The Global Alliance for Vaccines and Immunization.

Mr. Bickerstaff holds a B.S. in Engineering and a B.A. in Business Administration from Rutgers University (1978).

Michele Galen


Michele Galen is a strategic advisor to firms across pharmaceuticals, biotech, health start-ups and global health. Ms. Galen served as Global Head, Communications and Public Affairs, for Shire plc, serving as the lead communications and public affairs advisor on the $32 billion successful acquisition and integration of Baxalta. Previously, Ms. Galen led Global Communications in Switzerland for Novartis AG, where she spent 14 years in positions of increasing responsibility and served on several management boards. Earlier, Ms. Galen served as chief marketing officer for MPM Capital, Managing Director for public relations firm Burson-Marsteller, Legal Affairs Editor for Business Week magazine, and an attorney with Skadden, Arps, Slate, Meagher & Flom LLP. Ms. Galen is currently a board member for nonprofit Global Oncology and for MK&A, a global healthcare consulting firm. Ms. Galen received a B.A. from George Washington University, M.S. from the Columbia University Graduate School of Journalism, and J.D. from New York University School of Law.

Makarand Jawadekar, Ph.D.


Dr. Jawadekar is a pharmaceutical executive with over thirty-five years of experience, including 28 years at Pfizer Inc. Dr. Jawadekar brings extensive experience in pharmaceutical research and development, alliance management, contracting, outsourcing, benchmarking, drug delivery, formulations, clinical supply manufacturing and packaging, clinical trial materials, pharmaceutics, pharmaceutical sciences, and performance metrics. He also has deep knowledge and global experience working across the United States, Europe, India, and other parts of Asia, including Japan and China.

Dr. Jawadekar serves as a strategic advisor to pharmaceutical and biotechnology companies through his independent consultancy, founded in 2010. From 1982 to 2010, Dr. Jawadekar held various technical, management, and business development positions at Pfizer, Inc., including Director, Portfolio Management & Analytics, and Vice President, Asia Colleague Resource Group, for Pfizer Global R&D.

Dr. Jawadekar received his B.Pharm. from Shivaji University in 1972, M.Pharm. from the University of Bombay in 1974, and Ph.D. in Pharmaceutics from the University of Minnesota in 1982.

Terence A. Kelly, Ph.D.


Dr. Kelly is a scientific leader with both Pharma and Biotech experience and a track record of delivering high quality compounds into advanced clinical studies. He is well versed in chemistry, disease biology and the enabling technologies needed for innovative and efficient drug discovery from lead identification through clinical development. In particular, he has extensive hands on drug discovery and development experience in Inflammation, Cardiovascular and CNS disorders. Dr. Kelly has served as a director of Cardax, Inc. since June 2014.

Dr. Kelly is a founder of Kelly Pharma Research Consulting, LLC. Between 1990 and 2009, Dr. Kelly served in various scientific and executive positions at Boehringer Ingelheim, where after a successful early career developing LFA-1 antagonists, he led its US-based medicinal chemistry department comprising145 scientists in the high throughput screening, computational chemistry, structural biology, combinatorial chemistry and medicinal chemistry groups.

Dr. Kelly holds a B.S. degree in Chemistry at Rensselaer Polytechnic Institute (1982) and a Ph.D. degree in Chemistry at the University of Texas at Austin (1988). He completed postdoctoral work in natural products synthesis at Yale University (1988-1990) and holds an MBA from New York University, Stern School of Business (1998). Dr. Kelly is the co-author of over 25 scientific publications and served on the College of Natural Sciences Advisory Council for the University of Texas.

Elona Kogan


Ms. Kogan is a biotechnology executive with over twenty years of experience focused on building fast growing publicly traded companies in regulated industries.

During her career, Ms. Kogan has provided leadership for transactions valued at more than $10 billion by developing the strategic, operating, and legal direction for publicly traded biotechnology and pharmaceutical companies through joint ventures, partnerships, mergers and acquisitions, and other business combinations with companies including Pfizer Inc., Merck & Co., Inc., Alpharma, Inc., Otsuka Pharmaceutical, Co. Ltd., and Takeda Pharmaceutical, Co. Ltd.

Ms. Kogan has provided legal, government relations, and compliance leadership for biotechnology and pharmaceutical companies in a broad range of therapeutic areas including cardiovascular, abuse deterrent technology platform, neuroscience, and oncology. Ms. Kogan has played a key role in leading companies through the development of a robust research and development pipeline, successful product launches, commercialization, and mergers and acquisitions.

Ms. Kogan is a graduate of the Southwestern Law School SCALE Program. Ms. Kogan graduated cum laude from Columbia University, Barnard College, with a degree in economics.

David G. Watumull

President and CEO, Director

Mr. Watumull has more than twenty years experience as a biotechnology industry executive, analyst, and investment banker. He is co-founder of Cardax and co-inventor of the Cardax technology.

Previously, as CEO of Hawaii Biotech, he led efforts that resulted in more than $25 million in investor financing and $30 million in federal grant and contract funding. Hawaii Biotech’s dengue vaccine, which progressed significantly during his tenure from this funding, is undergoing late stage clinical development at Merck. He also started and led a West Nile virus vaccine program at Hawaii Biotech that achieved success in a human proof of concept study.

Prior to Hawaii Biotech, Mr. Watumull worked at Paine Webber as a biotech money manager and investment executive, First Honolulu Securities as a biotech money manager, biotech industry analyst, and investment banker, and Aquasearch as Executive Vice president, Finance and Strategic Direction. His clients during his analyst career included the Wisconsin Investment Board, the world’s largest biotech investor at that time. While at Paine Webber, Mr. Watumull helped obtain financing for Amgen, Genentech, and Centocor. At Aquasearch, he helped lead a dramatic increase in the company’s public market capitalization.

He was named one of Hawaii’s “Ten Who Made a Difference” by the Honolulu Star-Bulletin for 1994. He and/or Cardax have also received several other awards recognizing biotech and small business in Hawaii. Mr. Watumull is also past Vice-Chairman of the Hawaii Science and Technology Council, the industry’s trade association in Hawaii.

Mr. Watumull graduated from Punahou School and attended Claremont Men’s College (now Claremont McKenna), majoring in mathematics, and has lectured at Claremont McKenna and the University of Hawaii business school.